Home › Metastatic Cancer › Maryland
Metastatic Cancer clinical trials in Maryland
47 studies for Metastatic Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Maryland Oncology, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07562152Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Greater Baltimore Medical Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07222800Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Maryland Oncology Hematology, P.A., Annapolis
- Maryland Oncology Hematology, P.A., Bethesda
- Maryland Oncology Hematology, P.A., Brandywine
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- JHU Oncology Central Kit Services, Baltimore
- Johns Hopkins Hospital, Baltimore
- Oncology Investigational Drug Service (IDS), Baltimore
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06103864Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- John Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06915753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Johns Hopkins Hospital, Baltimore
- James M Stockman Cancer Institute, Frederick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- American Oncology Partners, PA, Bethesda
- James M Stockman Cancer Institute, Frederick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07174336A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06606990The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Sep 16, 2026 · NCT04927416Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT03907475The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Sep 9, 2026 · NCT03841617NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
- Johns Hopkins, Baltimore
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 8, 2026 · NCT07563829A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Aug 31, 2026 · NCT02133196Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05687136FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Johns Hopkins Kimmel Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
- Research Site, Baltimore
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Aug 18, 2026 · NCT06792695FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT05691517Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336REMASTer: REcurrent Brain Metastases After SRS Trial
- University of Maryland, Baltimore
Recruiting
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT05124912E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT05686226Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Advanced Molecular Imaging and Therapy, Glen Burnie
- United Theranostics - Chesapeake, Glen Burnie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06040541Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- University of Maryland, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT04617522A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- John Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 18, 2026 · NCT06757634Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Johns Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT05379985Studying TAK-243 in Patients With Advanced Cancer
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT06223542Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
- The Center for Cancer and Blood Disorders, Bethesda
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT06697301A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT07020221A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Maryland, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
RecruitingPhase 2/3
Ages 18 and older · Men · Updated Apr 8, 2026 · NCT04787744From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.